Articles from Advances in Gastrointestinal Cancer (June 1, 2007)

Title	Author	Type	Words
A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer.	Montenegro-Beltran, Paola; Carrato, Alfredo		1398
Annual meeting of the American Society of Clinical Oncology (ASCO), 2007.	Watkins, David	Conference notes	2028
Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment.	Labianca, Roberto		422
Epidermal growth factor receptor-targeted therapies in colorectal cancer.	Hamdulay, Parvez		3611
Epidermal growth factor receptor-targeted therapies in gastrointestinal cancer: the story so far.	Watkins, David; Cunningham, David	Editorial	958
Epidermal growth factor receptor-targeted therapies in oesophagogastric and pancreatic cancers.	Watkins, David; Mochlinski, Kazimierz		2190
Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan.	Van Cutsem, Eric		438
The development of epidermal growth factor receptor-targeted therapies in gastrointestinal malignancies.	Jackson, Christopher		2668
Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of a randomised phase II study.	Kohne, Claus-Henning		507
World Congress on Gastrointestinal Cancer, Barcelona, 2007.	Van Cutsem, Eric	Conference notes	1182